Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PARASAL SODIUM (aminosalicylate sodium) is an oral tablet small molecule under development by Century Therapeutics. The drug is currently in pre-launch stage as an NDA product with mechanism of action and specific indications not yet disclosed in available data.
Pre-Launch
Pre-launch stage means core team is building infrastructure for market entry; opportunities exist in regulatory affairs, medical affairs, and clinical development roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PARASAL SODIUM offers exposure to the high-stakes pre-launch environment where strategic medical and clinical leadership are critical to market readiness. The small linked job count reflects the current development stage, but team expansion is typical as approval approaches.
DirectorExecutive Medical Director
Worked on PARASAL SODIUM at Century Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.